A controlled trial of cyclosporine in patients with progressive membra. nous nephropathy. A controlled trial of cyclosporine in patients diagnosed with progressive membranous nephropathy (MGN) was carried out to determine whether cyclosporine (D) would be more effective than placebo (F) in reducing the rate of deterioration in renal function. Patients (N = 64) with MGN were placed on a restricted protein diet ( 0.9 gikg) and followed closely for 12 months (Part 1). Patients at high risk of progression based on an absolute loss in creatinine clearance (Car) of 8 ml/min and persistent nephrotic range proteinuria (Pr) were selected and randomly assigned to either (D) (N = 9) or (P) (N = 8) for 12 months (Part 2). No differences in the two groups were noted at entry. After 12 months, the improvement in Cr slope in mi/mm/month was significantly greater in the D patients (D + 2.1 vs. P + 0.5, mean difference 1.6; 95% CI 0.3 to 3.0, P < 0.02). This improvement was maintained in six of eight D (75%) over a mean follow-up period of 21 months. Daily Pr also improved with D (by month 3, D -4.5 g/day vs. P + 0.7 g/day, P = 0.02) and was sustained in six of eight (75%) D patients. When Pr was expressed as a function of their concurrent Ce,, the D versus P patients' time to halving was faster (P = 0.02) and absolute number higher (4/9 D vs 0/8 P). In the D group a trend towards worse hypertension and an increase in the number of transient rises in serum creatinine were noted. In progressive MGN, D is often effective in reducing both the rate of renal deterioration and Pr. These benefits extended for up to two years post-treatment.
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Worldwide, idiopathic membranous nephropathy is the most common cause of the nephrotic syndrome in adults and remains responsible for up to 6% of all cases of ESRD due to primary giomerulonephritis [1] [2] [3] [4] [5] [6] . Controlled prospective clinical trials in unselected patients with this disorder using either steroids alone [7] [8] [9] or cyclophosphamide alone [10] have shown marginal or no effect, although when prednisone is combined with chiorambucil a benefit has been demonstrated [11] [12] [13] . However, concerns about the long-term risks of such a drug combination, coupled with the recognition that up to one third of patients will spontaneously remit, has limited the utilization of this therapy. An alternate approach has been to treat only patients felt to be at high risk of progression. These studies have been uncontrolled with considerable variability in both the selection criteria and results [14] [15] [16] [17] [18] . The exception was a recently published controlled trial by Falk et al which failed to demonstrate any additional benefit when cyclophosphamide plus steroids was compared to a steroid-only treatment group [19] .
Cyclosporine is a potent immunosuppressive agent that has been used in an uncontrolled fashion and in a limited number of patients with idiopathic membranous nephropathy but with encouraging results [20] [21] [22] [23] [24] . We report the results from our controlled long-term trial which compared cyclosporine treatment to placebo in a group of patients with this disorder, who had prospective documentation of progressive deterioration in renal function.
Methods

Part 1
All recent ( 24 months) biopsy-proven cases of membranous nephropathy in patients aged 18 to 65 with proteinuria 1 g/day were eligible for the 12 month observation section of the study (Part 1). Exclusion criteria were clinically apparent or drug related secondary causes or laboratory evidence of hepatitis, disseminated lupus esythematosus or diabetes mellitus. After signing an informed consent, approved by each institution's review board all patients were placed on a 0.9 g/kg restricted protein, 90 mmoliday sodium diet, and the observation begun. The blood pressure target in all patients was 140/90 mm Hg supine, but the choice of agents as well as diuretic type and dose were at the discretion of the individual nephrologist. Monitoring of their clinical state, blood pressure and edema status, as well as laboratory tests including serum creatinine, electrolytes, urea, albumin and 24-hour urine estimates of urea, protein content and creatinine were required every four weeks. Absolute loss of function from baseline and the rate of deterioration in renal function as measured by the change in both creatinine clearance in mi/mini month and by reciprocal of creatinine were estimated by our registry computer program. It calculated a slope on each patient based on these laboratory tests and the elapsed time from study entry. The first slope was not done until a minimum of four points based on these monthly tests had been received.
Part 2
Any patient whose calculations between the fourth and twelfth month of Part 1 showed both a consistant and an absolute decline in Cr of 8 mi/mm and whose proteinuria remained at 3.5 The patients were randomly assigned to either cyclosporine (D) or placebo (P) in blocks stratified by center. The patients were masked in regards to their assignment, but for safety reasons the physician in charge was not. In addition to Part 1 tests, whole blood monoclonal immunoassayed cyclosporine trough levels and liver function estimates were monitored at 1, 2, 4, 6 and 8 weeks, and then monthly for 10 months. The same clinical and laboratory observations as in Part 1 were then performed every second month until death (N = 1), initiation of dialysis (N = 5), or censor date of study. Liquid cyclosporine, 100 mg/mI, was initiated at 3.5 mg/kg/day taken in two divided doses, and periodic adjustments were made as necessary to achieve a 12-hour trough level of between 110 and 170 jig/liter. The placebo was made of the identical carrier except cyclosporine was excluded. It was initially prescribed at 0.035 mI/kg/day, taken in two divided quantities with periodic arbitrary adjustments in dose to match the cyclosporine group.
The hypertension control goal was 140/90 mm Hg. The choice of agents was that of the patient's nephrologist, except no angiotensin converting enzyme inhibitors were allowed unless the patient had been on such therapy a minimum of three months prior to Part 2 entry.
A diagnosis of membranous nephropathy by the local pathologist based on light, immunofluorescence and electron microscopy was sufficient for entry to Part 1. All the renal pathology for patients who entered Part 2 was subsequently independently reviewed by a nephropathologist (SR) who was unaware of the patient's group assignment. The pathology was graded both by the classic staging method [25] and by an estimate of the degree of glomenilar obsolescence, interstitial fibrosis and infiltrate, tubular atrophy, and vascular changes. The latter four were all scored on a scale of 0 to 4+ (none, mild, moderate or severe).
Stop points
If the creatinine rose 30% above the Part 2 entry value and remained so despite a 50% reduction in test medication and adjustments in diuretic dose if intravascular volume was a concern, and a two week wait, the study drug was discontinued. Other stop points were a potassium> 6.0 mEq/liter, a doubling of entry value liver function tests, at the patient's request, or if complete remission of proteinuria occurred.
Statistical analysis
The primary end point was the difference in the D versus P groups change in renal function as measured by the slope of C. in ml/min/month after 12 months in Part 2 compared to Part 1. Since certain events could create an early stop point, the same analysis was repeated using the end point as the actual time the test medication was discontinued in any patient. Analysis was by both Wilcoxon and by Student's f-tests. Values in the tables are means SD unless otherwise indicated.
Other statistical tests used included Chi square tests for proportions and the nonparametric Mann Whitney rank sum test for comparing changes in proteinuria and standardized proteinuria (this latter term was the value of the 24-hour urine protein expressed in p.g/min divided by the concurrent Cr in ml/min). All tests were two tailed. Kaplan-Meier survival curves and the log rank test were used to look at time to events and remission of proteinuria rates. (SAS Institute, Inc.; Cary, NC, USA.) Results Sixty-four patients entered Part 1 and had a minimum of four months of observations. There were 47 males and 17 females with a mean age of 47.4 years, range, 19 to 65. There were 56 (87%) Caucasian, 1 (2%) Black, 2 (3%) Asian and 5 (8%) patients of mixed racial origin. Other clinical and laboratory characteristics at Part 1 entry are outlined in Table 1 . The mean months of observation in Part I was 10.6 with a range between 4 and 13.
Twenty-three patients fulfilled all of the Part 2 criteria, but three refused the study, one had sepsis as an explanation for decline in function, one was noncompliant and one had a level of renal function too low to risk cyclosporine therapy. Seventeen patients were thus eligible and consented to randomization.
Sixteen were Caucasian and one was Asian. Other demographic and renal function characteristics are depicted in Table 2 . No differences in clinical, laboratory or pathology features were observed at entry between the two groups.
The average nonrandomized patients' monthly slopes in C. n Part 1 were significantly less negative and more stable than the patients selected for Part 2 (-0.5 vs. -2.3, P < 0.005) and their slopes remained stable in a subsequent year of follow-up (-0.3) ( Table 3 ). The overall rate of deterioration in the placebo patients in mi/mm/month was unchanged in Part 1 versus Part 2 (-2.18 vs.
-2.05; Fig. 1 ) but a significant improvement was seen in the cyclosporine patients (-2.43 vs. -0.73, P < 0.02; Fig. 2 ). The improvement in renal function as measured by the change in slopes (Part 2 on medication minus Part 1) was also greater in the D versus P patients in both absolute and percentage terms [D + 1.7 (70% improvement) vs. P + 0.1 (7% improvement), mean difference 1.5 (95% CI 0.2 to 3.1)1 (Table 3) . When examined by nonparametric methods to account for the variations in slope, the P value remained unchanged (P < 0.02). This improvement was maintained at 12 months [D + 2.1 (88%) vs. P + 0.5 (23%), mean difference 1.6 (95% CI 0.3 to 3.0)]. When the same statistical tests were applied to the slopes of the reciprocal of creatinine, the results and P values were the same. Proteinuria in the D group was reduced by an average of 4.5 g/day versus P group increase of 0.7 g/day by month 3, P = 0.02. This overall improvement was maintained until the last follow-up (4.5 g/day vs. 9.2 g/day, P = 0.03; Table 4 ). Halving of proteinuria was seen in four of eight D versus none of eight P. In an attempt to account for the rapid changes in glomerular filtration rate, daily proteinuria was expressed as a function of the concurrent creatinine clearance (Fig. 3) . A significant improvement was seen in the D patients in both the time to (P < 0.02) and the number (6/8 D vs. 0/8 P) who halved their standardized proteinuria, and this particular marker of improvement persisted until their last follow-up in six of eight D versus zero of eight P.
The mean dose of cyclosporine was 3.8 mg/kg with a range between 2.5 and 4.9. An automatic dose reduction was reached because of a 30% rise in serum creatinine above Part 2 entry in 10 patients (6 D, 4 P) but with medication adjustment, this reversed in five D but none in P. One D patient died following an unrelated acute myocardial infarction after five months of treatment. His latest function prior to death showed improved proteinuria from 17.8 g/day at entry to 3.8 g/day prior to his death. Four patients (D2, P2) required the addition of antihypertensive therapy in Part 2 and the requirements increased in five other patients (D4, P1). None of the newly diagnosed hypertensive patients were given ACE inhibitors, and those on this therapy in Part 1 (Dl, P1) had no change in dosage during Part 2. Although there was a trend to a greater number and severity of hypertensive problems in the cyclosporine treated patients (P = 0.9), they were all maintained below the prescribed target of 140/90 mm Hg. Mean arterial pressure, based on monthly measurements was not different between D and P groups in Part 1 or Part 2. Other adverse effects were equal in the two randomized groups with respect to gastrointestinal complaints (D2, P1), tremor (Dl, P1), hirsutism (Dl, P1), and infections (Dl, P3). No malignancies were seen in any patient. Dietary compliance to the 0.9 g/kg protein restriction was checked by monthly urine urea quantitation and adherence noted in 80% of visits. Only two patients (Dl, P1)
were assessed as noncompliant in that their urine ureas indicated a dietary protein intake 30% above that prescribed in more than 20% of visits.
Discussion
The natural history of membranous nephropathy is variable with 10 to 45% reaching chronic or end-stage renal failure 5 to 10 Months from randomization tions [7] [8] [9] or have limited the trial to those with the best function [11] [12] [13] . Two recent studies using steroids alone demonstrated no benefit [8, 9] , and although a combination of a cytotoxic drug plus corticosteroids has been shown to be effective [12] , the recognition that many of these patients would have been stable or There were no statistical or clinical differences between the D and P patients at Part 2 entry (Table 2 ). After 12 months the cyclosporine treated patients showed an overall 88% slowing in their rate of decline of creatinine clearance compared to 23% in the placebo group. This improvement persisted for up to 40 months after the medication was discontinued in seven of eight (88%) D patients. The clinical relevance of the benefit of treatment is emphasized by the overall outcome. The CCr at Part 2 entry was similar in P versus D (46 ml/min vs. 51 mI/mm, P NS) but by two years six of eight P had progressed to less than 30% residual function (4 ESRD) compared to only two of eight in the D group (1 ESRD), with the remaining six averaging a C. of 45 mI/mm. Proteinuria was also significantly improved by cyclosporine (Table 4) , and although it rose transiently after the drug was discontinued in three patients, at last follow-up one D patient had normalized his proteinuria, six remained at less than 50% of their Part 2 entry value and two patients were unchanged. Decreasing proteinuria associated with a parallel decline in Cr is not indicative of a drug benefit. Proteinuria was therefore also expressed in terms of the patients' concurrent creatinine clearance. The time to halving of this ratio should more accurately reflect absolute improvement in glomerular permeability to protein because it accounts for changes in glomerular filtration rate. The time to this event was reduced in D patients compared to the P group (P < 0.02) and this marker of improvement remained beyond the test medication period in six of eight (75%) D patients versus none of the P group (Fig. 3) .
There are more precise techniques for measuring the changes in glomerular filtration rate than creatinine clearance [301. However, repeated measures, length of follow-up, plus utilization of the patients as their own controls, help to limit this problem [31, 32] . As well, no major intercurrent illnesses or purposeful loss of lean body mass of more than 10% was seen in any patient in Part 2. Thus, fluctuations in urine creatinine due to loss of muscle mass was not an issue. Obtaining similar results when the reciprocal of serum creatinine slopes were compared also helps strengthen our conclusions. Moreover, since a significant part of the error in C measurements, as filtration function fails, is due to the increased percentage of urine creatinine attributable to the amount of its tubular secretion, the overestimates of function should be greatest in patients with the lowest Car. This should bias against the D group since the P patients by the end of Part 2 had much lower Ccr values. This may well have been the explanation for an apparent slowing in the rate of decline in creatinine clearance in several of the P patients in their predialysis phase. Earlier uncontrolled studies have suggested there is improvement in both severity of proteinuria and stabilization of Cr in some MGN patients treated with cyclosporine [20-24, 33, 341 . Although the precise mechanism of its effect is unknown, recent data indicates a direct immunologic benefit of the drug on both glomerular barrier function and systemic cytokine levels in patients with MGN [24, 35] . There are, however, potential risks to this medication. Hypertension was more common in the D patients, but was readily controlled and the mean arterial pressure was equal in the two groups throughout the study. No patients required additional treatment with ACE inhibitor class medication. This data would support our contention that neither the hypertension control nor ACE inhibitor class drugs, indicated by some to improve proteinuria in MGN patients [36] , are the explanation for our observed results. Compliance to dietary protein restriction was equal in the two groups and is also therefore unlikely to be the explanation for the improvement observed. The only other significant adverse effect of cyclosporine was on serum creatinine concentration. Although the number of transient rises 30% above baseline was greater in the D patients (6 vs. 4), it was reversed in five of six (83%) of the D cases by a temporary reduction in dose, whereas medication reduction did not lead to improvement in any of the P patients. This suggests a major component was a drug-induced hemodynamic effect in the D patients versus the natural history of the disease as the explanation in the P patients. This is an important safety issue since we and other authors have suggested that the amount of cyclosporine should be adjusted down if creatinine rises in order to minimize the risk of long-term drug induced nephrotoxicity [20, 37] . Our mean and range of cyclosporine drug usage were where minimum chronic damage has been reported. The maintenance of the improved slope in Cr for up to two years post-cyclosporine would also indicate that we were in the safe drug dose range.
Previous authors have selected patients at high risk of progression in a number of different ways and then applied a variety of therapeutic agents. These drug routines have included pulse methylprednisolone [16] , combined chiorambucil and corticosteroids [14, 15] , prolonged cyclophosphamide plus other agents [17, 18, and even intravenous immunoglobulin G [41] . The results have varied and have sometimes been contradictory [14, 151. All have been uncontrolled. The need for a placebo group is underlined by the variations we observed even in our P patients despite our stringent selection criteria (Figs. 1 and 4) . This is further emphasized by the variation seen in the only other published controlled trial in preselected high risk patients [19] .
We recognize that the numbers in the randomized section of the trial are small. However, our selection criteria were rigid and followed established criteria that have been shown to accurately predict those patients most likely to progress to chronic renal insufficiency [26] . This type of selection both permits conclusions to be drawn from much smaller numbers and avoids needless treatment with potentially toxic drugs in patients who would do well with symptomatic management alone. Support for this type of preselection to improve the risk-benefit ratio of treatment has been the subject of two recent editorial reviews [42, 43] .
Whether reduced nephrotoxic risk but equal immunosuppressive effect could be obtained by either a shorter course or lower dose of cyclosporine than the routine used is unknown and needs further study. Similarly, if additional benefits could be derived by its use at an earlier stage of the disease needs to be addressed. However, our results do suggest that with careful monitoring, a course of cyclosporine is safe and often effective in both slowing the rate of decline in function and improving proteinuria in patients with proven progressive membranous nephropathy. Our data further suggest that this effect may persist for a considerable period even after the medication is discontinued.
